BNN.XETRA BRAIN Biotech AG

Basic Materials Biotechnology XETRA Stock Exchange
2.62 EUR
Close of Nov 5, 2026
2.13 3.74
Market cap
EUR 57.2M
P/E
-
P/B
9.62x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is BNN.XETRA undervalued?

Graham number

The Graham number of BRAIN Biotech AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BRAIN Biotech AG fundamental analysis

No fundamental analysis for BRAIN Biotech AG yet.

BRAIN Biotech AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BRAIN Biotech AG

BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of research-intensive development projects primarily for the life sciences industry. …

Full company profile